Healthcare / BiotechnologyTaipei Exchange
$32.60
+0.15 (+0.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-32.9M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.0%
↓Gross Margin
57.2%
↑Debt/Equity
0.61
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.4%
FCF CAGR
—
FCF margin
-2.1%
FCF / Net income
0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.58B · net income $-108.8M · FCF $-32.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.58B | $1.58B | $1.37B | $1.16B | $1.06B |
| Net Income | $-108.8M | $-108.8M | $-204.7M | $-561.3M | $-675.9M |
| EBITDA | $-19.8M | $-19.8M | $98.9M | $-1.04B | $-1.64B |
| EPS | — | — | -1.47 | -4.03 | -4.86 |
| Gross Margin | 57.2% | 57.2% | 54.9% | 53.3% | 8.3% |
| Operating Margin | -6.6% | -6.6% | -15.4% | -105.3% | -155.9% |
| Net Margin | -6.9% | -6.9% | -14.9% | -48.5% | -64.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.61 | 0.61 | 0.68 | 1.83 | 1.28 |
| Current Ratio | 5.41 | 5.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.9M | $-32.9M | $-20.8M | $-545.4M | $-1.29B |
| Returns | |||||
| ROE | -7.0% | -7.0% | -12.9% | -35.3% | -30.8% |
| Valuation | |||||
| EV/EBITDA | — | — | 42.54 | — | — |
| P/B | 2.93 | 2.93 | 2.86 | 3.82 | 2.07 |
| Growth & Yield | |||||
| Revenue Growth | 15.3% | 15.3% | 18.6% | 9.6% | — |
| EPS Growth | — | — | 63.5% | 17.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.47 → n/d
Residual
+2.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.